Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Apr 5, 2011


Fluidigm has appointed Evan Jones to its board of directors and its compensation committee. Jones is the managing member of jVen Capital, a life sciences-investment company. Prior to forming jVen Capital, he was co-founder, chairman, and CEO of Digene Corporation, a publicly traded biotechnology company focused on women's health and molecular-diagnostic testing.

He is currently executive chairman of OpGen, a genomics company focused in the areas of microbial genetics and DNA sequence analysis. He is director of CAS Medical Systems and Veracyte. He was chairman of Signature Genomic Laboratories from 2008 until the company was sold to Perkin-Elmer in May 2010.

Jones has a BA from the University of Colorado at Boulder and an MBA from the University of Pennsylvania's Wharton School.

Roche Diagnostics has appointed Robert Yates to head Roche Applied Science. He succeeds Manfred Baier, who will retire from the company at the end of the year. Yates will report to Roche Diagnostics COO Daniel ODay.

Most recently, Yates served as Roche Diagnostics' global head of business development and licensing. He has also held leadership positions in R&D, engineering and process management within Roche Diagnostics, both in the company's Indianapolis facility and in Roche's headquarters in Basel, Switzerland.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.